Therefore, the percentage of PD-L1 expression in tumor biopsies is used as a stratification factor for pembrolizumab administration in non-small cell lung cancer (NSCLC) or melanoma [1,2,3,4]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.